Pharm
Abatacept
search
Abatacept
, CTLA4-Ig
Mechanism
Extracellular CTLA4 fused to Fc of IgG1
Inhibits CD28 to CD80/CD66 binding
Increases
T-Cell Activation
threshold and inhibits
T-Cell
proliferation
Dosing
IV infusion: 10 mg/kg to 500, 750 or 1000 mg over 30 minutes
Initial: 0, 2 and 4 months and then every 4 months
Indications
Refractory
Rheumatoid Arthritis
Contraindications
Do not use with TNF
Antagonist
agent, and probably Anankira
Live virus
Vaccine
within the last 3 months
Type your search phrase here